Current CDC surveillance data show no active outbreaks meeting the agency's criteria for a Level 4 Travel Health Notice, which requires an extreme health risk with no effective precautions available. Ongoing monitoring of Ebola in the Democratic Republic of the Congo and Uganda, chikungunya, and other pathogens reflects moderate transmission without exponential growth or novel high-fatality strains that have historically prompted such designations. Official notices remain at Level 2 or 3, supported by enhanced entry screening rather than blanket avoidance advisories. With six months remaining in 2026, the absence of rapid escalation signals in recent situational reports underpins trader consensus favoring no new Level 4 issuance by year-end, though updated model runs or confirmed novel pathogen emergence could shift conditions.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于是
$71,755 交易量
$71,755 交易量
2026-12-31
是
$71,755 交易量
$71,755 交易量
2026-12-31
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Current CDC surveillance data show no active outbreaks meeting the agency's criteria for a Level 4 Travel Health Notice, which requires an extreme health risk with no effective precautions available. Ongoing monitoring of Ebola in the Democratic Republic of the Congo and Uganda, chikungunya, and other pathogens reflects moderate transmission without exponential growth or novel high-fatality strains that have historically prompted such designations. Official notices remain at Level 2 or 3, supported by enhanced entry screening rather than blanket avoidance advisories. With six months remaining in 2026, the absence of rapid escalation signals in recent situational reports underpins trader consensus favoring no new Level 4 issuance by year-end, though updated model runs or confirmed novel pathogen emergence could shift conditions.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
市场开放时间： Jan 19, 2026, 3:15 PM ET
交易量
$71,755结束日期
2026-12-31市场开放时间
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Current CDC surveillance data show no active outbreaks meeting the agency's criteria for a Level 4 Travel Health Notice, which requires an extreme health risk with no effective precautions available. Ongoing monitoring of Ebola in the Democratic Republic of the Congo and Uganda, chikungunya, and other pathogens reflects moderate transmission without exponential growth or novel high-fatality strains that have historically prompted such designations. Official notices remain at Level 2 or 3, supported by enhanced entry screening rather than blanket avoidance advisories. With six months remaining in 2026, the absence of rapid escalation signals in recent situational reports underpins trader consensus favoring no new Level 4 issuance by year-end, though updated model runs or confirmed novel pathogen emergence could shift conditions.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
交易量
$71,755结束日期
2026-12-31市场开放时间
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...Current CDC surveillance data show no active outbreaks meeting the agency's criteria for a Level 4 Travel Health Notice, which requires an extreme health risk with no effective precautions available. Ongoing monitoring of Ebola in the Democratic Republic of the Congo and Uganda, chikungunya, and other pathogens reflects moderate transmission without exponential growth or novel high-fatality strains that have historically prompted such designations. Official notices remain at Level 2 or 3, supported by enhanced entry screening rather than blanket avoidance advisories. With six months remaining in 2026, the absence of rapid escalation signals in recent situational reports underpins trader consensus favoring no new Level 4 issuance by year-end, though updated model runs or confirmed novel pathogen emergence could shift conditions.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题